Log In
Print
BCIQ
Print
Print this Print this
 

APX004

  Manage Alerts
Collapse Summary General Information
Company Apexigen Inc.
DescriptionHumanized mAb against VEGF receptor 2 (KDR/Flk-1; VEGFR-2)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat angiogenic diseases; Treat cancer
Regulatory Designation

Partner

Gansu Duyiwei Biotechnology Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today